FDA clears ID Biomedical to seek accelerated approval for Fluviral

The U.S. FDA has given ID Biomedical of Canada clearance to seek accelerated approval for its flu vaccine, enabling the firm to begin marketing Fluviral as early as the 2006 flu season. Some potential investors believe the company could still enter the U.S. market this winter if Chiron fails to return its vaccine to the market in time.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL